for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bioanalytical Systems, Inc.

BASI.OQ

Latest Trade

5.15USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.18

 - 

5.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.15
Open
--
Volume
--
3M AVG Volume
1.64
Today's High
--
Today's Low
--
52 Week High
5.40
52 Week Low
1.18
Shares Out (MIL)
10.50
Market Cap (MIL)
54.90
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2019 Bioanalytical Systems Inc Earnings Release

Latest Developments

More

Bioanalytical Systems Announces Launch Of Its New Contract Research Services Brand, Inotiv

BASi Announces Expansion Into Surgical Models And Medical Devices With Agreement To Purchase Pre-Clinical Research Services

Bioanalytical Systems Posts Q3 Loss Per Share Of $0.04

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bioanalytical Systems, Inc.

Bioanalytical systems, Inc. is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies. The research products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers, and medical research institutions. The Company supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. The contract research services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance and quality control testing.

Industry

Biotechnology & Drugs

Contact Info

2701 Kent Ave

+1.317.4634527

http://www.basinc.com/

Executive Leadership

Gregory Cole Davis

Interim Chairman of the Board

Robert Leasure

President, Chief Executive Officer, Director

Jill C Blumhoff

Chief Financial Officer, Vice President - Finance

Daniel Thomas Oakley

Chief Operating Officer

Michael Baim

Vice President - Bioanalytical Operations

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
1.45
Price To Book (MRQ)
5.33
Price To Cash Flow (TTM)
37.29
Total Debt To Equity (MRQ)
139.17
LT Debt To Equity (MRQ)
118.85
Return on Investment (TTM)
-7.28
Return on Equity (TTM)
-4.25

Latest News

Latest News

BRIEF-Bioanalytical Systems Q1 Earnings Per Share $0.00

* FOR THREE MONTHS ENDED DECEMBER 31, 2017, REVENUE AMOUNTED TO $5.4 MILLION, 13% DECREASE FROM $6.2 MILLION IN Q1 OF FISCAL 2017 Source text: (http://bit.ly/2HeJCqc) Further company coverage:

BRIEF-Bioanalytical Systems reports Q3 earnings per share of $0.03

* Qtrly revenue amounted to $5.8 million, up 15 percent Source text: (http://bit.ly/2uH6Zlw) Further company coverage:

BRIEF-BASI reports Q2 earnings per share $0.05

* Bioanalytical Systems Inc - board has directed management to seek alternatives that will enable company to repay its indebtedness to Huntington Bank

BRIEF-BASI Q1 EPS $0.00

* Bioanalytical Systems - board has directed management to seek alternatives to enable co to repay indebtedness to Huntington Bank in full

BRIEF-Bioanalytical Systems' CEO Jacqueline Lemke to resign

* Bioanalytical Systems - on Nov 2, Jacqueline Lemke informed board of her intent to resign from her positions of president and chief executive officer

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up